立中集团（300428）(300428.SZ)披露2025年年度业绩预告，公司预计归属于上市公司股东的净利润8.3 亿元至8.7亿元，同比增长17.38%至23.04%;归属于上市公司股东的扣除非经常性损益的净利润7.5亿元至 7.9亿元，同比增长23.42%至30.00%。 报告期内，公司聚焦主营业务，深化全球产业链布局，重点拓展新材料、新产品在新兴领域的市场应 用，提升高附加值产品占比，盈利能力持续提升。 ...

Core Viewpoint - The company, Lichung Group, forecasts a net profit attributable to shareholders of 830 million to 870 million yuan for the year 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - The net profit excluding non-recurring gains and losses is expected to be between 750 million and 790 million yuan, indicating a year-on-year increase of 23.42% to 30.00% [1] Group 1 - The company focuses on its main business and deepens its global industrial chain layout [1] - The company emphasizes the expansion of new materials and new products in emerging market applications [1] - The company aims to increase the proportion of high value-added products, leading to continuous improvement in profitability [1]

Group 1 - Postal Savings Bank announced a cash dividend distribution of 14.772 billion yuan for the first half of 2025, with a dividend of 1.23 yuan per 10 shares [1] - Xinke Mobile plans to reduce its shareholding by up to 1%, amounting to a maximum of 34.1875 million shares, due to funding needs [1] - Defu Technology signed a cooperation letter with a leading domestic CCL company to supply high-end electronic circuit copper foil products, which is expected to positively impact the company's performance in 2026 [1] Group 2 - Sanxia New Materials intends to acquire 40% equity of Lingang New Materials for a transaction amount of 0 yuan, which constitutes a related party transaction [2] - Fulim Precision plans to invest a total of 87 billion yuan in projects for the production of high-end lithium iron phosphate for energy storage, with the main project estimated at 60 billion yuan [3] - Heng Rui Pharmaceutical received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity in adults [3] Group 3 - Quartz Co. was fined 2.7 million yuan for commercial secret infringement, with the company being the victim in this case [5] - ST Renfu received approval for clinical trials of HW221043 tablets for late-stage solid tumors, with no similar drugs approved domestically or internationally [6] - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical robotics and smart manufacturing [6] Group 4 - Xusheng Group received a notification from a North American electric vehicle manufacturer for a project with an estimated total sales amount of approximately 7.8 billion yuan over its lifecycle [6] - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this does not significantly impact the company's operations [7] - Shengyang Technology's subsidiary is advancing a project with a global satellite operator in South America, focusing on software licensing and product delivery [7] Group 5 - Hefei China announced a 1% reduction in shares by its controlling shareholder, who terminated the reduction plan early to express confidence in the company's future [8] - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for 8.511 billion yuan, which will expand its business into drug delivery systems [10]

Core Viewpoint - Lichung Group (300428) forecasts a net profit attributable to shareholders of 830 million to 870 million yuan for the year 2025, representing a year-on-year growth of 17.38% to 23.04% [1] Group 1: Profit Growth Drivers - The increase in profit is primarily due to steady growth in production and sales across various business segments [1] - The aluminum alloy wheel segment's overseas capacity expansion is progressively operational, with facilities in Thailand and Mexico enhancing global supply capabilities and increasing sales to high-end customers [1] - The lithium hexafluorophosphate business benefits from market price recovery and the introduction of strategic investors, leading to improved capacity utilization and order volume [1] - Continuous optimization of product structure and customer matrix, along with active promotion of new materials and products in emerging markets such as new energy vehicles, humanoid robots, aerospace, and semiconductors, lays a foundation for enhanced profitability [1]

每经AI快讯，1月5日，立中集团公告称，立中集团发布2025年度业绩预告，预计归属于上市公司股东 的净利润为8.30亿元~8.70亿元，比上年同期增长17.38%~23.04%。报告期内，公司聚焦主营业务，深化 全球产业链布局，提升高附加值产品占比。业绩增长主要得益于各业务板块产销量上升，海外产能释 放，六氟磷酸锂业务扭亏为盈，以及新材料在新能源汽车、人形机器人等新兴领域应用拓展。 ...

Core Viewpoint - The company, Lichung Group, forecasts a net profit of 830 million to 870 million yuan for the year 2025, representing a year-on-year growth of 17.38% to 23.04% [1] Group 1: Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between 750 million to 790 million yuan, with a year-on-year increase of 23.42% to 30.00% [1] - The company anticipates total sales revenue of approximately 32 billion yuan for the year, with steady growth in production and sales across various business segments [2] Group 2: Business Growth Drivers - The aluminum alloy wheel segment is projected to sell 23.4 million units, while the recycled casting aluminum alloy segment is expected to reach 1.26 million tons, and the functional intermediate alloy segment is estimated at 120,000 tons [2] - The overseas production capacity in Thailand and Mexico is being effectively utilized, enhancing global supply capabilities and supporting sales growth from high-end customers [2] - The lithium hexafluorophosphate business has turned profitable since November, benefiting from market price recovery and increased capacity utilization [2] - The company is actively optimizing its product structure and customer matrix, focusing on new materials and products in emerging markets such as new energy vehicles, humanoid robots, aerospace, and semiconductors [2]

Core Viewpoint - Lichung Group (300428.SZ) forecasts a net profit of 830 million to 870 million yuan for the year 2025, representing a year-on-year growth of 17.38% to 23.04% [1] Group 1: Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between 750 million and 790 million yuan, with a year-on-year increase of 23.42% to 30.00% [1] - The company anticipates total sales revenue of approximately 32 billion yuan for the year, driven by steady growth in production and sales across various business segments [2] Group 2: Business Growth Drivers - The aluminum alloy wheel segment is projected to sell 23.4 million units, while the recycled casting aluminum alloy segment is expected to reach 1.26 million tons, and the functional intermediate alloy segment is estimated at 120,000 tons [2] - The overseas production capacity in the aluminum alloy wheel segment is being effectively utilized, with operations in Thailand and Mexico enhancing global supply capabilities [2] - The lithium hexafluorophosphate business has turned profitable since November, benefiting from market price recovery and increased capacity utilization [2] Group 3: Strategic Focus - The company is focusing on its core business and enhancing its global industrial chain layout, particularly in new materials and products for emerging markets [1] - Continuous optimization of product structure and customer matrix is being pursued, with applications in new energy vehicles, humanoid robots, aerospace, and semiconductors [2]

证券代码：300428 证券简称：立中集团 公告编号：2026-001 号 立中四通轻合金集团股份有限公司 2025 年年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 单位：万元 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的净 利润 | 盈利 83,000.00-87,000.00 | 盈利：70,711.57 | | | 比上年同期增长：17.38%-23.04% | | | 归属于上市公司股东的扣 除非经常性损益的净利润 | 盈利：75,000.00-79,000.00 | 盈利：60,767.93 | | | 比上年同期增长：23.42%-30.00% | | 计变更影响后的增幅区间为 45.14%-52.13%。 公司利润增长的主要原因：（1）公司各业务板块产销量稳步提升，其中铝 合金车轮板块销量预计 2,340 万只、再生铸造铝合金板块销量预计 126 万吨、功 能中间合 ...

Core Viewpoint - The company is actively engaging with domestic and international clients in the humanoid robot sector and is accelerating product validation and collaboration efforts [2] Group 1: Humanoid Robotics - The company is focusing on the humanoid robot field and is working to establish connections with clients both domestically and internationally [2] - There is an emphasis on accelerating product validation and the implementation of collaborations in this sector [2] Group 2: Aerospace Materials - The company is expanding the application scenarios of high-end materials in the commercial aerospace sector [2] - Relevant materials have been indirectly used in the manufacturing of critical components for aircraft, rockets, and spacecraft [2] Group 3: Global Supply Chain - The company has established a global production capacity through its overseas factories in Thailand and Mexico, enabling regional supply capabilities [2] - This setup allows the company to efficiently respond to global customer demands, including those from the Americas [2] - The international expansion of emerging businesses is supported by this robust supply chain [2]

Core Viewpoint - Lichung Group (300428.SZ) announced the renewal of the "Joint Action Agreement" among the Zang family members and its controlling shareholder, Tianjin Dong'an Brothers Co., Ltd., to maintain consistent decision-making and stability in the company's actual control [1] Group 1: Shareholder Agreements - The Zang family, including natural shareholders and indirect shareholders, has agreed to act in concert regarding their shareholder rights in Lichung Group and Tianjin Dong'an [1] - The renewal of the agreements was made to ensure the stability of the company's actual control and decision-making processes [1] - The total number of shares and the shareholding ratio held by the Zang family in Lichung Group remain unchanged after the renewal [1]